Skip to content
EntityQ2226212· pop 9· linked from 316 articles

satraplatin

Sign in to save

Also known as JM-216, Bis-acetatoamminedichlorocyclohexylamine platinum(IV), BMY 45594, BMY-45594, JM216

Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

~6 min read

Encyclopedic overview

6 sections
Contents
  • Mode of action
  • Clinical development
  • Side effects
  • Possible risks and complications
  • Detailed mechanism of action
  • References

Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

The drug has also been used in the treatment of lung and ovarian cancers. The proposed mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.

Excerpted from Wikipedia’s “satraplatin” article, available under the CC BY-SA 4.0 licence.